Rrad is known to inhibit cardiac hypertrophy through the CaMKII pathway with implications for heart failure35, and is associated with hypertrophic cardiomyopathy (HCM) phenotype in RRAD-deficient cell line36. Here, CAMK2G is linked to hypertrophic cardiomyopathy.